Chengdu Biostar Pharmaceuticals Ltd.

Phase I Main purpose: Determine the combined dosing regimen for the Phase I extension and Phase II; Compare the intracranial efficacy of the two treatment groups. Secondary purpose: Compare other intracranial and systemic efficacy of the two treatment groups; Compare the safety and tolerability of the two treatment groups. Phase II Main purpose: Evaluate the intracranial efficacy of Utidelon injection combined with bevacizumab in patients. Secondary purpose: Evaluate other intracranial and systemic efficacy of Utidelon injection combined with bevacizumab in patients; Evaluate the safety and tolerability of Utidelon injection combined with bevacizumab in patients; Explore the improvement of patients' quality of life QOL

Primary objectives: To evaluate the safety and tolerability of Utidelon Capsules in patients with advanced solid tumors, and to determine the maximum tolerated dose and dose-limiting toxicity. Secondary objectives: 1. To evaluate the absolute bioavailability of Utidelon Capsules relative to Utidelon Injection; 2. To evaluate the pharmacokinetic characteristics of Utidelon Capsules in patients with advanced solid tumors; 3. To preliminarily evaluate the efficacy and safety of Utidelon Capsules in patients with advanced solid tumors; 4. To recommend the dosage and dosing regimen for subsequent clinical trials.

To evaluate the efficacy and safety of eutilide combined with doxorubicin + cyclophosphamide (AC) chemotherapy versus docetaxel combined with doxorubicin + cyclophosphamide (AC) chemotherapy for neoadjuvant chemotherapy of HER2-negative early high-risk or locally advanced breast cancer